fresh funds

Houston biotech company raises $15M round led by Chinese health care investor

A Houston-based biotech startup has fresh funds to continue R&D on its products. Photo via Getty Images

A Houston-based biotech company that was founded by a University of Texas MD Anderson Cancer Center doctor has closed a fresh round of funding.

Cellenkos closed its $15 million series A round led by BVCF Management, based in Shanghai, China. The biotech company is developing novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders. Dr. Simrit Parmar of the University of Texas MD Anderson Cancer Center and Golden Meditech Holdings Limited founded the company.

Dr. Parmar's specialty is in Lymphoma Myeloma and experimental therapeutics. According to a news release, she is also the principal investigator of a research laboratory focused on umbilical cord blood-derived Treg cells including their isolation and ex-vivo expansion for generating clinically relevant doses for their application in autoimmune diseases and inflammatory disorders.

"We feel fortunate to welcome BVCF as a new investor. As I look ahead, we are committed to bringing our novel Treg cell therapies to patients in need around the world," says Dr. Parmar in a news release.

BVCF is a health care investment firm focused on growth-stage healthcare companies from around the world. The portfolio has a particular focus on innovative solutions that address unmet health needs in China.

"Cellenkos' innovative and transformative Treg cell therapy platform to address autoimmune and inflammatory disorders has the potential to significantly serve unmet patient needs. We are proud to lead the financing and support their groundbreaking efforts," says Dr. Zhi Yang, managing partner at BVCF, in the release.

The company has plans to launch a phase 1b trial of add on therapy with one of its products for the treatment of myelofibrosis patients. The fresh funds will allow the company to continue to scale and test its life-saving technology.

Trending News

Building Houston

 
 

Houston-based medical device and biotech startup Steradian Technologies has been recognized by the Bill and Melinda Gates Foundation. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

A female-founded biotech startup has announced that it has received a grant from the Bill & Melinda Gates Foundation.

Steradian Technologies has developed a breath-based collection device that can be used with diagnostic testing systems. Called RUMI, the device is non-invasive and fully portable and, according to a news release, costs the price of a latte.

“We are extremely honored to receive this award and be recognized by the Bill & Melinda Gates Foundation, a leader in global health. This funding will propel our work in creating deep-tech diagnostics and products to close the equity gap in global public health," says Asma Mirza, CEO and co-founder of Steradian Technologies, in the release. “The RUMI will demonstrate that advanced technology can be delivered to all areas of the world, ensuring the Global South and economically exploited regions receive access to high-fidelity diagnostics instead of solutions that are ill-suited to the environment.”

RUMI uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30-seconds, per the release, and will be the first human bio-aerosol specimen collector to convert breath into a fully sterile liquid sample and can be used for many applications in direct disease detection.

"As the healthcare industry continues to pursue less invasive diagnostics, we are very excited that the foundation has identified our approach to breath-based sample collection as a standout worthy of their support," says John Marino, chief of product development and co-founder. “We look forward to working with them to achieve our goals of better, faster, and safer diagnostics."

Founded in 2017, Steradian Technologies is funded and supported by XPRIZE, Johnson & Johnson’s Lung Cancer Initiative, JLABS TMCi, Capital Factory, Duke Institute of Global Health, and Johnson & Johnson’s Center for Device Innovation.

The amount granted by the Bill & Melinda Gates Foundation was not disclosed. The Seattle-based foundation is led by CEO Mark Suzman and co-chaired by Bill Gates and Melinda French Gatess.

Trending News